Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13938176 | 0.96 | STS (0.56) | STSMAPK1GPR119KMT2APTPN2 | |
| SCHEMBL1979225 | 0.90 | USP30 (0.50) | STSMAPK1GPR119KMT2AKDM4E | |
| SCHEMBL3917709 | 0.88 | GPR119 (0.51) | STSMAPK1GPR119KMT2APTPN2 | |
| SCHEMBL13938196 | 0.87 | FKBP1A (0.49) | STSMAPK1GPR119 | |
| SCHEMBL3266038 | 0.87 | YAP1 (0.60) | STSGPR119KDM4EPKMKEAP1 | |
| SCHEMBL13938199 | 0.86 | KDM4E (0.50) | STSMAPK1GPR119KMT2AKDM4E | |
| SCHEMBL1980404 | 0.86 | HSD17B10 (0.53) | STSMAPK1KMT2A | |
| SCHEMBL3266040 | 0.86 | STS (0.45) | STSMAPK1KMT2AHTT | |
| SCHEMBL13938169 | 0.86 | STS (0.49) | STSMAPK1GPR119KMT2AKDM4E | |
| SCHEMBL13938153 | 0.86 | POLB (0.45) | STSMAPK1KMT2AHTTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326840-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-1326834-B1 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | H LEE MOFFITT CANCER CT & RES (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-1326833-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1326833-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7304053-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304053-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7135483-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-6809093-B2 | DRUG RESISTANCE THERAPY | H. LEE MOFFITT CANCER & RESEARCH INSTITUTE, INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1326834-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | The Procter & Gamble Company (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326833-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | THE PROCTER GAMBLE CO. | 2002-07-25 | — | — | US | disclosed |
| WO-2002032868-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032869-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6376514-B1 | PIPERIDINE-DERIVED COMPOUNDS CONTAINING A QUINOLYL GROUP THAT INHIBITS P-GLYCOPROTEIN TRANSPORT PROTEIN ACTIVITY; FOR TREATING CANCER AND OTHER DISEASES | THE PROCTER & GAMBLE CO. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCB11 | STS 347/4885MAPK1 3186/4885GPR119 834/4885 |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | STS 568/4885MAPK1 3832/4885GPR119 1366/4885 |
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | ABCC1, SLC11A2, ABCB1 | STS 1786/4885MAPK1 4545/4885GPR119 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.